MyFinsight
Home
Blog
About
Proceeds from issuance of
common stock from...
$33,548K
Proceeds from exercise of
stock options
$176K
Proceeds from exercise of
warrants
$1K
Net cash provided by
(used in) financing...
$33,725K
(73415.22%↑ Y/Y)
Net change in cash,
cash equivalents and...
$17,336K
(-23.49%↓ Y/Y)
Canceled cashflow
$16,389K
Proceeds from maturities
of marketable...
$56,051K
(-51.49%↓ Y/Y)
Deferred revenue
$14,810K
(535.72%↑ Y/Y)
Accrued expenses and
other current...
$3,993K
(165.43%↑ Y/Y)
Stock-based compensation
expense
$3,036K
(-71.08%↓ Y/Y)
Accounts receivable
-$1,549K
(-71.92%↓ Y/Y)
Reduction in carrying
amount of right-of-use...
$1,454K
(-56.17%↓ Y/Y)
Accounts payable
$348K
(-60.85%↓ Y/Y)
Depreciation and
amortization expense
$292K
(-72.74%↓ Y/Y)
Other
$12K
(-75.00%↓ Y/Y)
Net cash provided by
investing activities
-$14,815K
(-121.77%↓ Y/Y)
Net cash used in
operating activities
-$1,574K
(96.53%↑ Y/Y)
Canceled cashflow
$56,051K
Canceled cashflow
$25,494K
Revenue from
collaboration agreements
$6,641K
Non-operating income
$2,788K
Purchases of marketable
securities
$70,829K
(49.68%↑ Y/Y)
Net loss
-$23,635K
(54.85%↑ Y/Y)
Purchases of property and
equipment, net
$37K
(-80.00%↓ Y/Y)
Canceled cashflow
$9,429K
Prepaid expenses and
other current and...
$1,659K
(141.75%↑ Y/Y)
Operating lease liability
-$1,588K
(43.95%↑ Y/Y)
Net accretion of
discounts on marketable...
$186K
(-86.36%↓ Y/Y)
Total operating
expenses
$33,064K
Back
Back
Cash Flow
C4 Therapeutics, Inc. (CCCC)
C4 Therapeutics, Inc. (CCCC)
source: myfinsight.com